

Special Issue

Cardiovascular Disease: Precision Medicine, Pharmacogenomics and Genetics

Message from the Guest Editor

Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for ~32% of global deaths. Genetic contributions, traditional risk factors, and their comorbidities are incompletely understood. In clinical practice, considerable interindividual variability in the response to cardiovascular pharmacotherapy, such as statins, ACEIs, and β -blockers, induces severe adverse events. Precision medicine integrates clinical and health record datasets with advanced panomics (i.e., genomics, transcriptomics, epigenomics, metabolomics, and microbiomics) to uncover vascular disease phenotypes and select the corresponding pharmacotherapeutics based on the framework of interactome networks. Personalized medicine offers the potential to optimize the benefit–risk profile of cardiovascular drugs by tailoring the diagnostic and treatment strategies according to individual patients with CVD. The purpose of this Special Issue is to host research and review papers on the modification of genetic variability in the response to cardiovascular drugs and their potential molecular mechanisms.

Guest Editor

Prof. Dr. Shanqun Jiang
School of Life Sciences, Anhui University, Hefei, China

Deadline for manuscript submissions

closed (15 July 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/196065

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))